In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles
Anne-Sophie Gremeau, Natasha Andreadis, Muhammad Fatum, Jo Craig, Karen Turner, Enda McVeigh, Tim Child, Anne-Sophie Gremeau, Natasha Andreadis, Muhammad Fatum, Jo Craig, Karen Turner, Enda McVeigh, Tim Child
Abstract
Objective: To compare the outcome of unstimulated in vitro maturation (IVM) and routine IVF/intracytoplasmic sperm injection (ICSI) for women with polycystic ovaries (PCO).
Design: Retrospective case-control study.
Setting: Fertility unit.
Patient(s): Ninety-seven patients undergoing IVM were compared with 97 patients undergoing IVF. All had PCO and matched for age, infertility diagnosis, and ovulatory status.
Intervention(s): In vitro maturation cycles were unstimulated and hCG was administered 35-40 hours before oocyte retrieval. Oocytes were matured in vitro for 24-48 hours before insemination by ICSI. Endometrial priming with E(2) and P was commenced from the day of egg retrieval and one to two embryos were transferred on days 2-5 of development. Standard long protocol IVF/ICSI was used in the control group.
Main outcome measure(s): Live birth rate per cycle and ovarian hyperstimulation syndrome (OHSS) rate.
Result(s): Overall, 65% of IVM eggs matured in vitro in the IVM group. Implantation rates were significantly higher in the IVF group (19.4% vs. 12.9%) as clinical pregnancy rates (50.5% vs. 19.6%) and live birth rates (44.3% vs. 16.5%) than in the IVM group. The OHSS rate was significantly higher in the IVF group (8.2% vs. 0%).
Conclusion(s): In vitro maturation is a safer and simpler alternative to conventional IVF for women with PCO. It avoids difficulties of gonadotropin stimulation and the risk of OHSS but has a significantly lower live birth rate. Current research projects aim to close the success gap between IVM and IVF.
Copyright © 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Source: PubMed